MX2020012030A - Lactamas funcionalizadas novedosas como moduladores del receptor 7 de 5-hidroxitriptamina y su método de uso. - Google Patents

Lactamas funcionalizadas novedosas como moduladores del receptor 7 de 5-hidroxitriptamina y su método de uso.

Info

Publication number
MX2020012030A
MX2020012030A MX2020012030A MX2020012030A MX2020012030A MX 2020012030 A MX2020012030 A MX 2020012030A MX 2020012030 A MX2020012030 A MX 2020012030A MX 2020012030 A MX2020012030 A MX 2020012030A MX 2020012030 A MX2020012030 A MX 2020012030A
Authority
MX
Mexico
Prior art keywords
modulators
hydroxytryptamine receptor
novel functionalized
group
lactams
Prior art date
Application number
MX2020012030A
Other languages
English (en)
Inventor
Daniel J Canney
Benjamin E Blass
Kevin M Blattner
Douglas A Pippin
Original Assignee
Univ Temple
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Temple filed Critical Univ Temple
Publication of MX2020012030A publication Critical patent/MX2020012030A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/96—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Las composiciones farmacéuticas de la invención comprenden derivados de lactamas funcionalizadas que tienen una acción modificadora de la enfermedad en el tratamiento de enfermedades asociadas con la desregulación de la actividad del receptor 7 de 5-hidroxitriptamina.
MX2020012030A 2018-05-11 2019-05-10 Lactamas funcionalizadas novedosas como moduladores del receptor 7 de 5-hidroxitriptamina y su método de uso. MX2020012030A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862670116P 2018-05-11 2018-05-11
PCT/US2019/031824 WO2019217890A1 (en) 2018-05-11 2019-05-10 Novel functionalized lactams as modulators of the 5-hydroxytryptamine receptor 7 and their method of use

Publications (1)

Publication Number Publication Date
MX2020012030A true MX2020012030A (es) 2021-03-29

Family

ID=66655471

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012030A MX2020012030A (es) 2018-05-11 2019-05-10 Lactamas funcionalizadas novedosas como moduladores del receptor 7 de 5-hidroxitriptamina y su método de uso.

Country Status (13)

Country Link
US (1) US20220306629A1 (es)
EP (1) EP3790859A1 (es)
JP (2) JP7429652B2 (es)
KR (1) KR20210020182A (es)
CN (1) CN112437768A (es)
AU (1) AU2019267846A1 (es)
BR (1) BR112020023072A2 (es)
CA (1) CA3110799A1 (es)
EA (1) EA202092328A1 (es)
MA (1) MA52567A (es)
MX (1) MX2020012030A (es)
TW (1) TW202016072A (es)
WO (1) WO2019217890A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970223B1 (en) 2013-03-11 2020-04-15 Temple University Of The Commonwealth System Of Higher Education Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use
US10544117B2 (en) 2014-09-10 2020-01-28 Temple University—Of the Commonwealth System of Higher Education 5-hydroxytryptamine receptor 7 activity modulators and their method of use
JP7107955B2 (ja) 2016-11-15 2022-07-27 テンプル・ユニバーシティ－オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション ５－ヒドロキシトリプタミン受容体７の新規調節因子およびその使用方法
EP3600290A4 (en) 2017-03-21 2020-08-12 Temple University - Of The Commonwealth System of Higher Education NEW SIGMA 2 RECEIVER MODULATORS AND THEIR OPERATING PROCEDURE
MA49017A (fr) 2017-03-21 2020-02-05 Univ Temple Modulateurs du récepteur 7 de la 5-hydroxytryptamine et utilisation de ces derniers en tant qu'agents thérapeutiques
BR112022009374A2 (pt) * 2019-11-13 2022-08-09 Univ Temple Novas lactamas funcionalizadas como moduladores do receptor 7 de 5- hidroxitriptamina e seu método de uso

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2647785B1 (fr) * 1989-05-31 1991-09-06 Adir Nouveaux derives de la pyrrolidone, leur procede de preparation et les compositions pharmaceutiques les renfermant
DE4127404A1 (de) * 1991-08-19 1993-02-25 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
GB9912701D0 (en) * 1999-06-01 1999-08-04 Smithkline Beecham Plc Novel compounds
TWI319387B (en) * 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
EP1875899A1 (en) 2006-06-29 2008-01-09 Laboratorios Del Dr. Esteve, S.A. Use of 5HT7 receptor agonists for the treatment of pain
WO2010069390A1 (en) 2008-12-19 2010-06-24 Nokia Siemens Networks Oy Method and device for data processing in an udwdm network and communication system comprising such device
US20130287705A1 (en) 2010-11-03 2013-10-31 Mcmaster University Method of treating mucosal inflammation
EP2970223B1 (en) * 2013-03-11 2020-04-15 Temple University Of The Commonwealth System Of Higher Education Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use
US10544117B2 (en) * 2014-09-10 2020-01-28 Temple University—Of the Commonwealth System of Higher Education 5-hydroxytryptamine receptor 7 activity modulators and their method of use

Also Published As

Publication number Publication date
CA3110799A1 (en) 2019-11-14
US20220306629A1 (en) 2022-09-29
TW202016072A (zh) 2020-05-01
JP7429652B2 (ja) 2024-02-08
KR20210020182A (ko) 2021-02-23
MA52567A (fr) 2021-03-17
WO2019217890A8 (en) 2020-12-17
JP2024028680A (ja) 2024-03-04
EA202092328A1 (ru) 2021-04-08
EP3790859A1 (en) 2021-03-17
AU2019267846A1 (en) 2020-12-03
WO2019217890A1 (en) 2019-11-14
JP2021523179A (ja) 2021-09-02
BR112020023072A2 (pt) 2021-02-02
CN112437768A (zh) 2021-03-02

Similar Documents

Publication Publication Date Title
MX2020012030A (es) Lactamas funcionalizadas novedosas como moduladores del receptor 7 de 5-hidroxitriptamina y su método de uso.
NZ765590A (en) Diaryl substituted 5,5-fused ring compounds as c5ar inhibitors
MX2022009907A (es) Moduladores novedosos del receptor 7 de 5-hidroxitriptamina y sus metodos de uso.
PH12018500763A1 (en) New spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
CR20200584A (es) Compuestos tetrahidro-1h-pirazino [2,1-a] isoindolilquinolina para el tratamiento de enfermedades autoinmunes
ZA201907746B (en) 6-5 fused rings as c5a inhibitors
CR20220234A (es) Degradadores de moléculas pequeñas de helios y procedimientos de uso
PH12017500161A1 (en) 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
MX2019014292A (es) Anillos 5-5 fusionados como inhibidores c5a.
MX2020014156A (es) Oxadiazoles como agonistas de los receptores muscarinicos m1 y/o m4.
MX2010004003A (es) N-fenil-pirrolidinilmetlipirrolidin amidas sustituidas y uso terapeutico de las mismas.
PH12017500170A1 (en) 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors
MX2022006807A (es) Análogos de rapamicina y usos de estos.
MX2017001453A (es) Compuestos de 6,7-dihidropirazolo[1,5-a]pirazin-4(5h)-ona y su uso como moduladores alostericos negativos de receptores de glutamato metabotropico subtipo 2 (mglur2).
MX368214B (es) Compuestos de amida como agonistas del receptor de la 5-hidroxitriptamina 4 (5-ht4).
GEP20247585B (en) Furoindazole derivatives
MX2023000677A (es) Compuestos moduladores de receptor de estrogeno.
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
MX2017005715A (es) Potentes moduladores de gamma-secretasa.
MX2019014272A (es) Compuestos policiclicos y usos de los mismos.
MX2021011986A (es) Metodos de tratamiento de dolor neuropatico.
MX2017016939A (es) Novedosas antagonistas 5-ht2.
MX2020003185A (es) Nuevos compuestos heterociclicos.
PH12021550143A1 (en) Pyridopyrimidines as histamine h4-receptor inhibitors
NZ775905A (en) Pyrrolo-pyridazine derivatives as muscarinic m1 receptor positive allosteric modulators